Mohamed Alorabi

Mohamed Alorabi

Auto-generated profile, based on publicly available information

Mohamed Alorabi

Department of Clinical Oncology, Ain Shams University Hospitals, Cairo, Egypt

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 April 2020 in Journal of Community Health
Verified
Journal Article
Open access
PDF file
AAAhmed Samir Abdelhafiz
Ahmed Samir Abdelhafiz
ZMZeinab Mohammed
Zeinab Mohammed
MIMaha Emad Ibrahim
Maha Emad Ibrahim
HZHany H. Ziady
Hany H. Ziady
MAMohamed Alorabi
Mohamed Alorabi
ESEman A. Sultan
Eman A. Sultan
Coronavirus disease 2019 (COVID-19) has been recognized as a pandemic by the World Health Organization. Global efforts have been exerted to prevent the spreading of the disease through political decisions together with personal behaviors, which depend on awareness of the public. The goal of this study is to assess the knowledge, perceptions and attitude of the Egyptian public towards the COVID-19 disease. We conducted a cross-sectional survey about these points, which was distributed among adult Egyptians. Five hundred and fifty nine persons completed the survey. The mean knowledge score was 16.39 out of 23, gained mainly though social media (66.9%), and the internet (58.3%). Knowledge was significantly lower among older, less educated, lower income participants, and rural residents. Most participants (86.9%) were concerned about the risk of infection. While 37.6% thought that their salary will be continued if they become isolated, 68.5% believed that it should be continued during this period. About 73.0% were looking forward to get the vaccine when available. In general, participants had a good knowledge about the disease and a positive attitude towards protective measures. This knowledge is gained mainly through novel media channels, which have pros and cons. Although the government has taken major steps to educate the public and limit the spread of the disease, more effort is needed to educate and support the lower economic strata. If a vaccine or a treatment is approved, we recommend a government control over its use to preserve the rights of the vulnerable and needy groups.

1 July 2016 in Clinical Lung Cancer
Verified
Journal Article
Closed access
AGApar Kishor Ganti
Apar Kishor Ganti
VSValerie K. Shostrom Shostrom
Valerie K. Shostrom Shostrom
MAMohamed Alorabi
Mohamed Alorabi
WZWeining (Ken) Zhen
Weining (Ken) Zhen
AMAlissa S. Marr
Alissa S. Marr
AKAnne Kessinger
Anne Kessinger

1 March 2016 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
MAMohamed Alorabi
Mohamed Alorabi
NSNicole A. Shonka
Nicole A. Shonka
AGApar Kishor Ganti
Apar Kishor Ganti

26 May 2015 in Expert Review of Anticancer Therapy
Verified
Journal Article
Closed access
OAOmar Abdel-Rahman
Omar Abdel-Rahman
MAMohamed Alorabi
Mohamed Alorabi
Cardiac toxicity is one of the most important long-term toxicities experienced by cancer survivors so that survival rate due to anticancer therapy may be negatively affected due to cardiac complications. Thus, the search for novel methods to lower the incidence of treatment-related cardiotoxicity is a priority for all cancer-related disciplines. In this review, we provide an overview of the available preclinical and clinical data evaluating the role of angiotensin-converting enzyme inhibitors in the prophylaxis of cardiac dysfunction secondary to anthracyclines and trastuzumab use. The available clinical data suggest some degree of protective utility for the use of some angiotensin-converting enzyme inhibitors against anthracycline-related cardiotoxicity while the data are scarce with regard to a similar role for patients receiving trastuzumab.

12 June 2025 in Future Oncology
Verified
Journal Article
Closed access
AKAbanoub Samir Karam
Abanoub Samir Karam
SASherif Abdelwahab
Sherif Abdelwahab
MDMai Mohamed Ali Ezz El Din
Mai Mohamed Ali Ezz El Din
MAMohamed Osama Alorabi
Mohamed Osama Alorabi
Pleural mesothelioma (PM) is a rare aggressive cancer linked to asbestos exposure, with limited treatment options, especially in low-resource settings. While immune checkpoint inhibitors show promise, access remains limited in many countries. This prospective study was conducted at Ain Shams University Hospital from November 2022 to December 2024. 42 patients with unresectable PM and no progression after 4-6 cycles of platinum-pemetrexed chemotherapy were randomized 1:1 to receive switch-maintenance gemcitabine (1000 mg/m2 on days 1 and 8 every 21 days) or best supportive care (BSC). Progression-free survival (PFS), overall survival (OS), and toxicity (Common Terminology Criteria for Adverse Events CTCAE v5.0) were assessed. Maintenance gemcitabine significantly improved PFS in unresectable PM (8.9 vs. 5.2 months, p = 0.022), confirmed in univariate analysis (HR = 0.505, p = 0.040) but not multivariate (p = 0.069). OS also favored gemcitabine (16.2 vs. 13.4 months, p = 0.138). Multivariate analysis linked gemcitabine (p = 0.043), females, cisplatin use, and partial response to initial therapy with better OS, while ECOG II and occupational exposure predicted worse OS. Adverse events were manageable. Maintenance gemcitabine significantly improved PFS and was well tolerated, offering a practical and affordable treatment option for PM. www.clinicaltrials.gov identifier is NCT05660616.

7 September 2017 in Expert Review of Anticancer Therapy
Verified
Journal Article
Closed access
SASherif Hassanien Ahmed
Sherif Hassanien Ahmed
NENoha Elbaghdady
Noha Elbaghdady
MAMohamed Alorabi
Mohamed Alorabi
Introduction: The approval of multiple biological therapies as a first line treatment for metastatic renal cell carcinoma (mRCC) in the last decade have made the selection of the best treatment between these drugs, especially tyrosine kinase inhibitors (TKIs), a great challenge to oncologists and patients. The four TKIs recommended by the National Comprehensive Cancer Network guidelines in this setting have a relatively similar mechanism of action and analogical adverse events. Areas covered: In this article, the two published American Society of Clinical Oncology frameworks are applied to calculate the net health benefits of the four TKIs used as the first line in mRCC and this was balanced against their monthly cost. The available clinical data that is present for each drug has been displayed and compared to the use of the ASCO frameworks. Expert commentary: There is an urgent need to develop a comprehensive model incorporating all relevant aspects of each drug together. Oncologists should consider all data available for the drugs in order to give the patients an informed opportunity to select the best drug fitting for them.